Cite
PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia.
MLA
Vuorio, A., and P. T. Kovanen. “PCSK9 Inhibitors for COVID-19: An Opportunity to Enhance the Antiviral Action of Interferon in Patients with Hypercholesterolaemia.” Journal of Internal Medicine, vol. 289, no. 5, May 2021, pp. 749–51. EBSCOhost, https://doi.org/10.1111/joim.13210.
APA
Vuorio, A., & Kovanen, P. T. (2021). PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia. Journal of Internal Medicine, 289(5), 749–751. https://doi.org/10.1111/joim.13210
Chicago
Vuorio, A, and P T Kovanen. 2021. “PCSK9 Inhibitors for COVID-19: An Opportunity to Enhance the Antiviral Action of Interferon in Patients with Hypercholesterolaemia.” Journal of Internal Medicine 289 (5): 749–51. doi:10.1111/joim.13210.